STOCK TITAN

Rosalind Group Reports ~9.9% Position in Myomo (MYO) with Pre-Funded Warrants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Rosalind Advisors, Rosalind Master Fund L.P., Steven Salamon and Gil Aharon report shared beneficial ownership of 7,359,046 securities of Myomo, Inc., representing approximately 9.9% of the company’s outstanding common stock based on 37,801,070 shares reported by the issuer. The reported total comprises 3,595,788 shares of common stock and 3,763,258 shares issuable upon exercise of pre-funded warrants.

The filing states the pre-funded warrants include a blocker provision that prevents exercise to the extent it would push beneficial ownership above 9.99%, so the actual number of shares beneficially owned after giving effect to blockers is lower. Each reporting person discloses no sole voting or dispositive power and shared voting and dispositive power over the 3,595,788 common shares. The reporting persons certify the securities were acquired in the ordinary course and not to influence control of the issuer.

Positive

  • Full disclosure of a material ~9.9% position by Rosalind entities enhances transparency for shareholders
  • Blocker provision on pre-funded warrants limits immediate exercise above 9.99% and reduces sudden control shifts
  • Clear voting and dispositive power breakdown (0 sole power; 3,595,788 shared voting/dispositive power) clarifies influence

Negative

  • Concentration near 10% represents a sizable single-party stake that could influence perception of shareholder alignment
  • Significant warrant exposure (3,763,258 pre-funded warrants) could affect future dilution if blocker provisions change
  • Shared control structure may complicate attribution of intent despite disclaimers by the adviser and portfolio manager

Insights

TL;DR: A disclosed near-10% position with warrant exposure is material but limited by blockers; further monitoring advised.

The Schedule 13G/A shows a combined reported position of 7,359,046 securities equal to ~9.9% of the outstanding common stock, split between 3,595,788 common shares and 3,763,258 pre-funded warrants. The blocker provision explicitly restricts warrant exercise above 9.99%, which constrains any immediate dilution or voting power increase. Shared voting/dispositive power and the advisory relationships are clearly disclosed, and the filers represent passive intent. For investors, this is a material ownership disclosure but not an overt control action.

TL;DR: Transparency on ownership and blocker mechanics reduces governance risk while signaling significant shareholder concentration.

The filing provides clear allocation of voting and dispositive power and an explicit statement that the adviser and portfolio manager disclaim beneficial ownership, which helps clarify governance lines. The presence of a near-10% holder is notable for board and shareholder dynamics, yet the blocker on pre-funded warrants limits immediate escalation toward control thresholds. This disclosure improves market transparency without indicating a change in corporate control.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 37,801,070 shares of the Issuer's common stock outstanding as of August 11th, 2025, in accordance with information provided by the issuer. However, as more fully described in Item 4, the securities reported in rows (6), (8), and (9) show the number of shares of Common Stock that would be issuable upon exercise of such reported securities and do not give effect to blocker provisions. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8), and (9). (6) 3,595,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,595,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,595,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 3,595,788 shares of Common Stock 3,763,258 shares of Common Stock issuable upon exercise of pre-funded warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:08/11/2025
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:08/11/2025
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:08/11/2025
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:08/11/2025

FAQ

What stake does Rosalind report in Myomo (MYO)?

The reporting persons disclose a combined beneficial interest of 7,359,046 securities, representing approximately 9.9% of Myomo’s common stock.

How is the 7,359,046 total composed?

It consists of 3,595,788 shares of common stock and 3,763,258 shares issuable upon exercise of pre-funded warrants.

Do the filers have sole voting or dispositive power over these shares?

No. Each reporting person reports 0 sole voting power and 3,595,788 shared voting and dispositive power over the common shares.

What is the effect of the blocker provision mentioned in the filing?

The blocker provision prevents exercise of pre-funded warrants to the extent that doing so would increase beneficial ownership above 9.99%, so the actual exercisable ownership is limited.

Did the filers state their purpose for acquiring the securities?

Yes. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.
Myomo

NYSE:MYO

MYO Rankings

MYO Latest News

MYO Latest SEC Filings

MYO Stock Data

35.86M
35.62M
6.99%
66.68%
3.84%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
BOSTON